Hostname: page-component-cd9895bd7-dzt6s Total loading time: 0 Render date: 2024-12-21T18:40:10.617Z Has data issue: false hasContentIssue false
  • English
  • Français

Beyond the monoamine hypothesis: mechanisms, molecules and methods

Published online by Cambridge University Press:  16 April 2020

I. Hindmarch
I. Hindmarch*
Affiliation:
HPRU Medical Research Centre, University of Surrey, Egerton Road, Guildford, Surrey, UK
*
*Corresponding author.
Get access

Summary

The first effective antidepressants (monoamine oxidase inhibitors and tricyclic antidepressants) relied on their ability to augment serotonin and noradrenaline levels at the synapse. Forty years later, the same biological model led to the supremacy of the serotonergic hypothesis to explain not only the pathophysiology of depressive illness, but also the neuropharmacological basis for obsessive compulsive disorder, phobias, posttraumatic stress disorder, and even generalized anxiety disorder. It could be argued that the blinkered view of depression as a solely serotonergic phenomenon has not only restrained and limited research into other potential systems, but has also slowed down the discovery of putative antidepressant drugs. While some might argue that the hypothalamic-pituitary-adrenal (HPA) axis explains an individual’s sensitivity to depression, there are others who equally claim that the most likely explanations are to be found in the neuropsychopharmacology of the immune system or even through reductions in hippocampal volume. There is a richness of possibilities regarding the mechanisms for antidepressant activity embracing theoretical, pharmacological and clinical data. However, the methods by which putative antidepressants are assessed and their clinical efficacy demonstrated are not always robust. That current clinical comparisons of antidepressants rarely show major differences in efficacy between existing molecules could be taken as an indication that “all drugs are the same” or perhaps, more insightfully, as an indication that the ubiquitous Hamilton depression (HAM-D) rating scales are not sensitive to inter-drug differences, even though pronounced pharmacodynamic differences between molecules are easily demonstrated. Any advances in the development of new antidepressants will have to find not only original compounds but also unique psychometric tests by which the drugs can be assessed in a sensitive, reliable, and valid manner.

Keywords

Antidepressant activityMonoamine hypothesisNew diagnostic methodOriginal compound
Type
Research Article
Information
European Psychiatry , Volume 17 , Issue S3: A new pharmacology of depression: the concept of synaptic plasticity , July 2002 , pp. 294s - 299s
Copyright
Copyright Éditions scientifiques et médicales Elsevier SAS 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

To be presented at ECNP Barcelona, 5-9 October 2002, during the symposium “A new pharmacology of depression: the concept of synaptic plasticity.”

References

Asher, RMyxoedematous madness. Br Med J 1949;2:331–334.CrossRefGoogle ScholarPubMed
Bourin, MFiocco, AJClenet, FHow valuable are animal models in defining antidepressant activity?. Hum Psychopharmacol Clin Exp 2001;16:9–21.CrossRefGoogle ScholarPubMed
Bremner, JDDoes stress damage the brain?. Biol Psychiatry 1999;45:797–805.CrossRefGoogle ScholarPubMed
Bremner, JDNarayan, MAnderson, ERStaib, LHMiller, HLCharney, DSHippocampal volume reduction in major depression. Am J Psychiatry 2000;157:115–118.CrossRefGoogle ScholarPubMed
Cameron, HAWooley, CSMcEwen, BSGould, EDifferentiation of newly born neurons and glia in the dentate gyrus of the adult rat. Neuroscience 1993;56:337–344.CrossRefGoogle ScholarPubMed
Carpenter, WTBunney, WEAdrenal cortical activity in depressive illness. Am J Psychiatry 1971;128:31–40.CrossRefGoogle ScholarPubMed
Connor, TJLeonard, BEDepression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci 1998;62:583–606.CrossRefGoogle ScholarPubMed
Czéh, BMichaelis, TWatanabe, TFrahm, Jde Biurrun, Gvan Kampen, Met al. Stress-induced changes in cerebral metabolites, hippocampal volume and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci USA 2001;98:12796–12801.CrossRefGoogle ScholarPubMed
Dinan, TGNovel approaches to the treatment of depression by modulating the hypothalamic-pituitary-adrenal axis. Hum Psychopharmacol Clin Exp 2001;16:89–93.CrossRefGoogle ScholarPubMed
Duman, RSHeninger, GRNestler, EJA molecular and cellular theory of depression. Arch Gen Psychiatry 1997;54:597–606.CrossRefGoogle ScholarPubMed
Duman, RSMalberg, JThome, JNeural plasticity to stress and antidepressant treatment. Biol Psychiatry 1999;46:1181–1191.CrossRefGoogle ScholarPubMed
Eriksson, PPerfileva, EBjork-Eriksson, TAlborn, ANordborg, CPeterson, Det al. Neurogenesis in the adult human hippocampus. Nat M 1998;4:1313–1317.CrossRefGoogle ScholarPubMed
Gibbons, JLMcHugh, PRPlasma cortisol in depressive illness. J Psychiatr Res 1962;1:162–162.CrossRefGoogle ScholarPubMed
Gould, EMcEwen, BSTanapat, PGalea, LAFuchs, ENeurogenesis in the dentate gyrus of the adult tree-shrew is regulated by psychosocial stress and NMDA receptor activation. J Neurosci 1997;17:2492–2498.CrossRefGoogle ScholarPubMed
Gould, ETanapat, PMcEwen, BSFlugge, GFuchs, EProliferation of granule cell precursors in the dentate gyrus of adult monkeys is diminished by stress. Proc Natl Acad Sci USA 1998;95:368–371.CrossRefGoogle ScholarPubMed
Halaris, APiletz, JEImidazoline receptors: possible involvement in the pathophysiology and treatment of depression. Hum Psychopharmacol Clin Exp 2001;16:65–69.CrossRefGoogle ScholarPubMed
Hammen, CDavila, JBrown, GEllicott, AGitlin, MPsychiatric history and stress: predictors of severity of unipolar depression. J Abnorm Psychol 1992;101:45–52.CrossRefGoogle ScholarPubMed
Hindmarch, IRidout, FA placebo-controlled investigation into the effects of paroxetine and mirtazapine on car driving performance. Conference proceedings. Chicago, IL: American Psychiatric Association; 2000.Google Scholar
Holsboer, FGerken, AVon Bardeleben, Uet al. Human corticotropin-releasing hormone in depression. Biol Psychiatry 1986;21:601–611.CrossRefGoogle ScholarPubMed
Holsboer, FLauer, CJSchreiber, WKrieg, JCAltered hypothalamic-pituitary-adrenocortical regulation in healthy subjects at high familial risk for affective disorders. Neuroendocrinology 1995;62:340–347.CrossRefGoogle ScholarPubMed
Horrobin, DFPhospholipid metabolism and depression: the possible roles of phospholipase A2 and coenzyme A-independent transacylase. Hum Psychopharmacol Clin Exp 2001;16:45–52.CrossRefGoogle ScholarPubMed
Hyman, SENestler, EJThe molecular foundations of psychiatry. Washington, DC: American Psychiatric Press; 1993.Google Scholar
Jackson, IMThyrotropin-releasing hormone and corticotropin-releasing hormone — what’s the message?. Endocrinology 1995;136:2793–2794.CrossRefGoogle ScholarPubMed
Jackson, IMThe thyroid axis and depression. Thyroid 1998;8:951–956.CrossRefGoogle ScholarPubMed
Jackson, IMLuo, LGAntidepressants inhibit the glucocorticoid stimulation of TRH expression in cultured hypothalamic neurons. J Invest M 1998;46:470–474.Google ScholarPubMed
Jacobson, LSapolsky, RMThe role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenal axis. Endocr Rev 1991;12:118–134.CrossRefGoogle Scholar
Leonard, BENeuropharmacology of antidepressants that modify central noradrenergic and serotonergic function: a short review. Hum Psychopharmacol Clin Exp 1999;14:75–81.3.0.CO;2-X>CrossRefGoogle Scholar
Lôo, HSaiz-Ruiz, JCosta e Silva, JAet al. Efficacy and safety of tianeptine in the treatment of depressive disorders in comparison with fluoxetine. J Affect Disord 1999;56:109–118.CrossRefGoogle ScholarPubMed
Maes, MThe immunoregulatory effects of antidepressants. Hum Psychopharmacol Clin Exp 2001;16:95–103.CrossRefGoogle ScholarPubMed
Magarinos, AMcEwen, BFlugge, GFuchs, EChronic psychosocial stress causes apical dendritic atrophy of hippocampal CA3 pyramidal neurons in subordinate tree-shrews. J Neurosci 1996;6:3534–3540.CrossRefGoogle Scholar
Magarinos, AMDeslandes, AMcEwen, BSEffects of antidepressants and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress. Eur J Pharmacol 1999;371:113–122.CrossRefGoogle ScholarPubMed
Malberg, JEEisch, AJNestler, EDuman, RSChronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000;15:9104–9110.CrossRefGoogle Scholar
Malberg, JEShirayama, YSDuman, RSThe effect of antidepressant treatment and learned helplessness training on hippocampal neurogenesis in the adult rat. Abstr Soc Neurosci. 2001;27:974–974 6.Google Scholar
Manji, HKPotter, WZLennox, RHSignal transduction pathways. Molecular targets for lithium's actions. Arch Gen Psychiatry 1995;52:531–543.CrossRefGoogle ScholarPubMed
McEwen, BSStress and hippocampal plasticity. Annu Rev Neurosci 1999;22:105–122.CrossRefGoogle ScholarPubMed
McKittrick, CRMagarinos, AMBlanchard, DCBlanchard, RJMcEwen, BCSakai, RRChronic social stress reduces dendritic arbors in CA3 of hippocampus and decreases binding to serotonin transporter sites. Synapse 2000;36:85–94.3.0.CO;2-Y>CrossRefGoogle ScholarPubMed
Montgomery, SAHenry, JMcDonald, Get al. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994;9:47–53.CrossRefGoogle ScholarPubMed
Nemeroff, CBThe corticotropin-releasing factor (CRF) hypothesis of depression: new findings and new directions. Mol Psychiatry 1996;1:336–342.Google ScholarPubMed
Nemeroff, CBPsychopharmacolgy of affective disorders in the 21st century. Biol Psychiatry 1998;44:517–525.Google Scholar
Nestler, EJAntidepressant treatments in the 21st century. Biol Psychiatry 1998;44:526–533.CrossRefGoogle ScholarPubMed
Pinder, ROn the feasibility of designing new antidepressants. Hum Psychopharmacol Clin Exp 2001;16:53–59.CrossRefGoogle ScholarPubMed
Pineyro, GBlier, PAutoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol Rev 1999;51:533–591.Google ScholarPubMed
Plotsky, PMOwens, MJNemeroff, CBPsychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis. Psychiatr Clin N Am 1998;21:293–307.CrossRefGoogle ScholarPubMed
Post, RMTransduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992;149:999–1010.Google ScholarPubMed
Riedel, WJSchoenmakers, EVermeeren, AO'Hanlon, JFThe influence of trazodone treatment on cognitive functions in outpatients with major depressive disorder. Hum Psychopharmacol Clin Exp 1999;14:499–508.3.0.CO;2-1>CrossRefGoogle Scholar
Rubin, RTPhillips, JJSadow, TFMcCracken, JTAdrenal gland volume in major depression: increase during the depressive episode and decrease with successful treatment. Arch Gen Psychiatry 1995;52:213–218.CrossRefGoogle ScholarPubMed
Sandler, MNeurotrophins: possible role in anxiety and affective disorders. Hum Psychopharmacol Clin Exp 2001;16:61–64.CrossRefGoogle Scholar
Sapolsky, RMStress, glucocorticoids, and damage to the nervous system: the current state of confusion. Stress 1996;1:1–19.CrossRefGoogle ScholarPubMed
Sapolsky, RMGlucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 2000;57:925–935.CrossRefGoogle ScholarPubMed
Sartorius, NConcepts of depression: sporadic revolutions of continuous evolution. Hum Psychopharmacol Clin Exp. 2001;16:S3–S6CrossRefGoogle ScholarPubMed
Sheehan, DVRaj, BATrehan, RRKnapp, ELSerotonin in panic disorder and social phobia. Int Clin Psychopharmacol 1993;8:63–77.CrossRefGoogle ScholarPubMed
Sheline, YLWang, PWGado, MHCsernansky, JGVannier, NWHippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA 1996;93:3908–3913.CrossRefGoogle ScholarPubMed
Song, CThe interaction between cytokines and neurotransmitters in depression and stress: possible mechanism of antidepressant treatments. Hum Psychopharmacol Clin Exp 2000;15:199–211.3.0.CO;2-T>CrossRefGoogle ScholarPubMed
Sonino, NFava, GABelluardo, PGirelli, MEBoscaro, MCourse of depression in Cushing's syndrome: response to treatment and comparison with Grave's disease. Horm Res 1993;39:202–206.CrossRefGoogle Scholar
Stanley, NFairweather, DBHindmarch, IEffects of fluoxetine and dothiepin on 24-h activity in depressed patients. Neuropsychobiology 1999;39:44–48.CrossRefGoogle Scholar
Van Praag, HMPast expectations, present disappointments, future hopes or psychopathology as the rate-limiting step of progress in psychophamacology. Hum Psychopharmacol Clin Exp 2001;16:3–8.CrossRefGoogle ScholarPubMed
Watanabe, YGould, EDanield, DCCameron, HMcEwen, BTianeptine attenuates stress-induced morphological changes in the hipppocampus. Eur J Pharmacol 1992;222:157–162.Google Scholar
Wilde, MIBenfield, PTianeptine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression. Drugs 1995;49:411–439.CrossRefGoogle ScholarPubMed
Wittchen, H-USchuster, PLieb, RComorbidity and mixed anxiety-depressive disorder: clinical curiosity or pathophysiological need?. Hum Psychopharmacol Clin Exp. 2001;16:S21–S30CrossRefGoogle ScholarPubMed
Young, EAHaskett, RFMurphy-Weinberg, VWatson, SJAkil, HLoss of glucocorticoid fast feedback in depression. Arch Gen Psychiatry 1991;48:693–699.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.